What question did this study set out to answer?

To determine whether vascular healing, scaffold resorption, and luminal enlargement observed after bioresorbable vascular scaffold implantation persist at five years.

January 20, 2016EuroInterventionOpen Access

Percutaneous left atrial appendage occlusion in patients with non-valvular atrial fibrillation: implantation and up to four years follow-up of the AMPLATZER Cardiac Plug

View Full Paper

Ask AI

Bookmark

To determine whether vascular healing, scaffold resorption, and luminal enlargement observed after bioresorbable vascular scaffold implantation persist at five years.
Evaluated 8 of 16 patients from the ABSORB cohort A at the Thoraxcenter Rotterdam undergoing invasive follow-up at five years.
Assessed coronary vessels using coronary angiography, intravascular ultrasound (IVUS), virtual histology, optical coherence tomography (OCT), and acetylcholine vasomotion testing.
Minimum luminal diameter trended higher from two to five years (1.95±0.37 mm vs. 2.14±0.38 mm; p=0.09), and IVUS showed mean lumen area increased to 6.96±1.13 mm² at five years from 6.17±0.74 mm² at six months (p=0.06), driven by plaque reduction from 9.17±1.86 mm² to 7.57±1.63 mm² (p=0.03).
OCT imaging revealed complete disappearance of scaffold struts alongside a smooth endoluminal vessel lining and increased lumen areas.
Target coronary segments demonstrated restored normal vasomotion with no evidence of endothelial dysfunction during acetylcholine provocation testing.

Structured PICO

Population

8 patients from the Thoraxcenter Rotterdam cohort of the ABSORB cohort A study, mean age 65.1, 75% male, with coronary artery disease.

Intervention

First-generation everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) implantation

Outcome

Long-term vascular response and scaffold assessment at 5 years using quantitative coronary angiography, vasomotion test, greyscale intravascular ultrasound (IVUS), virtual histology, and optical coherence tomography (OCT)surrogate

At five years, the first-generation everolimus-eluting bioresorbable vascular scaffold is fully resorbed, with restored endothelial function and persistent late luminal enlargement without adaptive vessel remodeling.

Limitations

Small sample size (n=8)
Exploratory analysis without formal hypothesis testing
Single-centre follow-up

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Suggests ongoing plaque reduction may drive late lumen gain after BVS; hypothesis-generating and should not yet change practice.

Cite This Study

A 2016 study studied this question.

synapsesocial.com/papers/6a8232b4e5668b15782a535f https://doi.org/10.4244/eijy14m10_12

Topics

Coronary artery disease Percutaneous coronary intervention Coronary CT angiography Chronic total occlusion PCI

View Full Paper

Ask AI

Bookmark

Percutaneous left atrial appendage occlusion in patients with non-valvular atrial fibrillation: implantation and up to four years follow-up of the AMPLATZER Cardiac Plug

Key Points

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Topics

Percutaneous left atrial appendage occlusion in patients with non-valvular atrial fibrillation: implantation and up to four years follow-up of the AMPLATZER Cardiac Plug

Key Points

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider